On Wednesday, U.S. regulators announced that Johnson & Johnson’s Covid-19 vaccine being developed by its subsidiary Janssen Pharmaceuticals in Belgium is effective at preventing moderate to severe cases of the disease. The jab has been deemed safe with 66 percent efficacy and the FDA is likely to approve it for use in the U.S. within days.
The Ad26.COV2.S vaccine can be stored for up to three months in a refrigerator and requires a single shot, unlike some of the other Covid-19 vaccines currently in use that need special freezing units and two doses. It will also require less medical personnel and should speed up the pace of he vaccination campaign considerably.
The United States has ordered 100 million doses of Johnson & Johnson’s vaccine according to tracking conducted by Duke University but its rollout is set to be hindered by production shortfalls. The company committed to delivering 10 million doses by the end of February but it recently states that only 4 million are going to be ready to ship. By the end of March, the company hopes to distribute 20 million doses.
This chart shows confirmed orders for the Janssen Ad26.COV2.S vaccine.
Wall Street Examiner Disclosure: Lee Adler, The Wall Street Examiner reposts third party content with the permission of the publisher. The opinions expressed in these reposts are not those of the Wall Street Examiner or Lee Adler, unless authored by me, under my byline. I curate posts here on the basis of whether they represent an interesting and logical point of view, that may or may not agree with my own views. Some of the content includes the original publisher's promotional messages. No endorsement of such content is either expressed or implied by posting the content. All items published here are matters of information and opinion, and are neither intended as, nor should you construe it as, individual investment advice. Do your own due diligence when considering the offerings of information providers, or considering any investment.